

**Fig. 1. Conditional *Rest* knockout mice.** (A) In the conditional *Rest* knockout (KO) mice, exon 4 of *Rest* can be removed by doxycycline (Dox) exposure. (B) Pregnant mice with *Rest* conditional KO embryos were treated with doxycycline to delete the *Rest* alleles from the embryos in utero (E1.5–5.5). The growth retardation phenotype is detectable at E9.5 and E10.5.

is upregulated in *Rest*<sup>1lox/1lox</sup> mouse ESCs (supplementary material Fig. S1), indicating again that our *Rest* KO cells are equivalent to the *Rest* null cells.

A previous study using conventional KO mice revealed that mice lacking the *Rest* gene die during early embryonic development (Chen et al., 1998). When we administered doxycycline to the *Rest* conditional KO embryos to delete the *Rest* gene in utero (E1.5–5.5), we observed lethality of the embryos carrying the *tetO-Cre* allele at ~E10.5 with a growth retardation phenotype, which was accompanied by the loss of GFP signals, indicating that the phenotype of the conventional KO mice could be recapitulated in our *Rest* conditional KO mice (Fig. 1B).

#### Genetic ablation of *Rest* in non-neuronal cells outside of the central nervous system in vitro

Previous studies suggest that *Rest* is expressed in a variety of non-neuronal cells to suppress the neuronal differentiation of these cells. Indeed, the conventional *Rest* KO mice showed ectopic expression


of *Rest* target genes, such as *Tuj1* (*Tubb3*), in non-neuronal cells outside of the brain (Chen et al., 1998). Therefore, to elucidate whether *Rest* ablation can induce the expression of *Rest* target genes in non-neuronal cells, we used mouse embryonic fibroblasts (MEFs) containing floxed *Rest* alleles and doxycycline-inducible *Cre* alleles (*Rest*<sup>2lox/2lox</sup>; *Rosa26::rtTA*; *Col1a1::tetO-Cre*). The *Rest* conditional KO MEFs were treated with doxycycline for 3 days starting 1 day after the seeding of the MEFs (passage 1). Seven days after the seeding of the MEFs, the MEFs were examined for GFP expression by FACS analysis. Three weeks after the seeding of the MEFs, they were analyzed by immunocytochemistry with a *Tuj1* antibody to detect expression of the neural cell marker. The expression of *Rest* target genes was also examined by real-time RT-PCR 3 weeks after the seeding of the MEFs.

Consistent with the recombination, FACS analysis revealed a decreased GFP signal in the *Rest* conditional KO MEFs treated with doxycycline (Fig. 2A). As demonstrated in a previous study using conventional KO mice, deletion of *Rest* caused an increase in the expression of *Tuj1* in MEFs (Fig. 2B) (Chen et al., 1998). The real-time RT-PCR revealed that MEFs treated with doxycycline expressed a significantly reduced level of *GFP* and *Rest* (Fig. 2C). We found that this was associated with increased expression of *Syt4*, *Tubb3* and *Calb1*, which contain RE1 sites and are targets of the *Rest* repressor complex (Chong et al., 1995; Johnson et al., 2008; Schoenherr and Anderson, 1995; Schoenherr et al., 1996) (Fig. 2C). We also found that *Stmn2*, a *CoRest*-independent target of *Rest*-mediated repression, was also derepressed in MEFs by doxycycline exposure (Fig. 2C). These results indicate that *Rest* target genes are rapidly derepressed upon the loss of *Rest* in MEFs. However, *Bdnf*, which also contains an RE1 site and is a target of the *Rest* repressor complex in ESCs/NSCs (Johnson et al., 2008; Yamada et al., 2010), did not show any detectable derepression in doxycycline-treated MEFs (Fig. 2C).

Although we confirmed that removal of the *Rest* *CoRest* binding site induces ectopic neuronal gene expression in non-neuronal cells outside of the brain, it remains unclear whether *Rest* ablation can actually induce neuronal differentiation in non-neuronal cells. In the present study, despite the observed increase in the expression of neuronal genes such as *Syt4*, *Tubb3*, *Calb1* and *Stmn2* after ablation of *Rest* in MEFs, the morphology of the *Tuj1*-expressing cells did not change (Fig. 2B). In addition, the expression of *Fsp1* (*SI00a4*), a marker for fibroblasts (Strutz et al., 1995), was not decreased in the *Tuj1*-expressing MEFs (supplementary material Fig. S2). These findings suggest that *Rest* ablation in non-neuronal cells leads to ectopic neuronal gene expression, but that its ablation is not sufficient to induce transdifferentiation into neuronal cells (Vierbuchen et al., 2010).

We also examined the effect of *Rest* ablation in adult non-neuronal cells in vitro using tail tip fibroblasts (TTFs) containing the floxed *Rest* alleles and doxycycline-inducible *Cre* alleles. After exposure to doxycycline, we detected significant upregulation of the *Rest* target genes *Syt4*, *Tubb3*, *Calb1* and *Stmn2* in the TTFs, which was accompanied by the downregulation of *Rest* and *GFP* expression (supplementary material Fig. S3). Consistent with the results in MEFs, we failed to detect derepression of *Bdnf* or downregulation of *Fsp1* in TTFs after *Rest* ablation (supplementary material Fig. S3). We also conditionally deleted the *Rest* *CoRest* binding site in adult mice by the administration of doxycycline in the drinking water, and examined the expression of *Rest* target genes in the adult tail tissues. We confirmed the derepression of *Rest* target genes in the adult tail tissues after genetic ablation of *Rest* in vivo (supplementary material Fig. S4).





**Fig. 2. The conditional deletion of *Rest* in mouse embryonic fibroblasts leads to derepression of *Rest* target genes.** (A) FACS analysis revealed a decreased signal for GFP fluorescence in doxycycline-treated mouse embryonic fibroblasts (MEFs) 7 days after seeding of the MEFs. The dashed line indicates the GFP signal at the peak of the histogram of the control cells for comparison. (B) The conditional deletion of *Rest* in MEFs resulted in an increased number of Tuj1-positive cells in vitro. Tuj1 expression was also observed in some postmitotic neuronal cells with long axons, which were likely to be contaminating neuronal cells present in the MEF culture. Scale bars: 100  $\mu$ m. (C) Transcript levels of *Rest*, *GFP* and *Rest* target genes. The expression levels of the *Rest* target genes *Syt4*, *Tubb3*, *Calb1* and *Stmn2* were significantly upregulated, whereas the expression levels of *Rest* and *GFP* were downregulated after *Rest* ablation in MEFs. No significant change was detectable in the *Bdnf* expression level. Transcript levels were normalized to  $\beta$ -actin levels. The data are presented as average values with s.d. of nine independent samples. \*,  $P < 0.00001$ ; \*\*,  $P < 0.0005$ .

### In vitro ablation of *Rest* in neuronal progenitor cells


*Rest* is downregulated in the brain as gestation progresses (Ballas et al., 2005). We first examined the expression of *Rest* in the developing mouse brain. The conditional KO alleles contain IRES-*GFP* sequences at the 3' UTR of the *Rest* gene, which enable us to detect the expression and distribution of *Rest* by the GFP signals. By analyzing GFP expression, we confirmed that cells in the brain at E13.5 actually express the *Rest* gene (Fig. 3A).

In order to investigate the effect of genetic ablation of *Rest* during neurogenesis in vitro, we generated neurospheres from the brains of E13.5 *Rest* conditional KO embryos carrying the doxycycline-inducible *Cre* alleles. The primary neurospheres were passaged to form secondary neurospheres. Doxycycline was administered for 3 days starting 1 day after the passage of the primary neurospheres (passage 1). When we measured the number of secondary

neurospheres in order to compare the formation of neurospheres in the presence and absence of doxycycline, the number of neurosphere cells was not significantly different 1 week after passage, regardless of doxycycline exposure (Fig. 3B). By contrast, the number of cells constituting the neurospheres exposed to doxycycline was significantly decreased after long-term culture of the neurospheres (Fig. 3C), suggesting that the ablation of *Rest* inhibited the growth of the neurospheres. Since a recent study demonstrated that *Rest* ablation in cultured neurosphere cells actually results in decreased proliferative activity (Gao et al., 2011), the decreased proliferative activity might be responsible for the decreased number of cultured cells upon doxycycline treatment in vitro.

We next cultured *Rest* conditional KO neurospheres (*Rest*<sup>2lox/2lox</sup>; *Rosa26::rtTA*; *Colla1::tetO-Cre*) under differentiation conditions. To examine the effects of *Rest* ablation on neuronal differentiation, the





**Fig. 3. Rest ablation in in vitro cultured neuronal cells.** (A) FACS analysis for GFP fluorescence. The *Rest*<sup>2lox</sup> allele contains IRES-GFP sequences at the 3'UTR of the *Rest* gene, which allows visualization of *Rest* expression via GFP signals. Cells in the E13.5 mouse brain expressed GFP, suggesting that *Rest* is expressed in the developing brain. Dashed line represents the GFP signal at the peak of the histogram of the control cells for comparison. (B) The number of neurosphere cells in the presence and absence of doxycycline. The data are presented as the mean number of neurosphere cells in eight independent experiments (R1-R8). Error bars indicate s.d. (C) The number of cells constituting neurospheres in the presence and absence of doxycycline. Doxycycline-treated neurospheres grew more slowly than control neurospheres. Error bars indicate s.d. (D) The percentage of Tuj1-positive cells among total differentiated neurosphere cells after genetic deletion of *Rest*. The number of Tuj1-positive cells among total cells was significantly increased after *Rest* ablation. The data are presented as average values with s.d. of three independent samples. (E) The expression of *Syt4* and *Calb1* is derepressed after *Rest* ablation in neurosphere-derived differentiated cells. Transcript levels were normalized to  $\beta$ -actin levels. The data are presented as average values with s.d. of six independent samples. (F) The percentage of Gfap-positive cells among total differentiated neurosphere cells after genetic deletion of *Rest*. The data are presented as average values with s.d. of three independent samples. \*,  $P < 0.001$ ; \*\*,  $P < 0.00005$ .


doxycycline treatment was started 1 day after seeding the neurospheres in adherent culture, and the cells were treated with doxycycline for an additional 3 days. The adherent spheres were stained with anti-Tuj1 and anti-Gfap antibodies 1, 2 and 3 weeks after doxycycline exposure (Fig. 3D and supplementary material Fig. S5) and we counted the number of Tuj1-positive or Gfap-positive cells and DAPI-positive (total) nuclei in three independent areas of 1.5 mm<sup>2</sup> to calculate the proportion of Tuj1-positive or Gfap-positive cells. The doxycycline-treated cells contained a significantly increased percentage of Tuj1-positive cells among total cells than the control non-treated cells after 2 and 3 weeks of the treatment (Fig. 3D). In addition, a real-time PCR analysis revealed that the expression levels of *Syt4* and *Calb1* increased in the neurosphere adherent culture after genetic ablation of *Rest* (Fig. 3E). By contrast, the percentage of Gfap-positive glial cells among total cells was not altered (Fig. 3F), suggesting that ablation of *Rest* does not have a significant effect on glial differentiation in vitro in this experimental condition.

Because the Tuj1 and Gfap double-negative cells in the adherent spheres decreased after doxycycline treatment, *Rest* ablation may induce Tuj1 expression in such Tuj1 and Gfap double-negative

cells. Immunocytochemical analysis of doxycycline-treated neurosphere cells revealed that a subset of non-neuron-like cells expresses Tuj1 and/or calbindin, whereas non-neuron-like cells in the control neurospheres did not express these markers (supplementary material Fig. S6A,B). Consistent with a previous study (Gao et al., 2011), we observed a small number of cells that express both Tuj1 and Gfap, suggesting the misexpression of *Rest* target genes (supplementary material Fig. S6C). Collectively, these results suggest that derepression of *Rest* target genes occurred in the adherent neurosphere cells upon *Rest* ablation, and that this derepression might play a role in the promotion of neuronal differentiation.


#### The in vivo effects of *Rest* ablation on gene expressions in non-neuronal and neuronal cells of the developing embryo

In the E13.5 mouse embryo the expression level of *Rest* in the limb was higher than that in the brain (supplementary material Fig. S7). By contrast, the expression level of *Rest* target genes was higher in the brain than in the limb (supplementary material Fig. S7).



**Fig. 4. In vivo genetic ablation of *Rest* in developing embryos.** (A) Neuronal gene expression levels in the brains of E13.5 embryos and adult mice. The expression of *Syt4* and *Calb1* was significantly higher in the adult brain, suggesting that *Rest* neuronal target genes are still repressed in the E13.5 brain. The transcript levels were normalized to  $\beta$ -actin. The data are presented as average values with s.d. of six independent samples. (B) The experimental protocol for recombination of the *Rest* alleles in vivo. Pregnant mice with *Rest* conditional KO embryos were treated with doxycycline for 5 days, and embryos were sacrificed at E13.5. GFP fluorescence was decreased in embryos with the *tetO-Cre* allele, as compared with control embryos without the *tetO-Cre* allele. (C) The in vivo expression of *Rest* target genes in the brain. Although the expression levels of *Rest* and *GFP* were significantly downregulated, the expression levels of most *Rest* target genes were not derepressed in the brains of *Cre+* embryos. Transcript levels were normalized to  $\beta$ -actin. The data are presented as average values with s.d. of four independent samples. (D) The expression of *Rest* target genes in the peripheral tissues (limb) in vivo. The expression of *Syt4*, *Tubb3*, *Calb1* and *Stmn2* was derepressed after genetic deletion of *Rest*. Transcript levels were normalized to  $\beta$ -actin. The data are presented as average values with s.d. of four independent samples. (E) A microarray analysis of E13.5 brain and non-neuronal (limb) tissue after genetic ablation of *Rest*. *Rest* binding genes in neuronal stem cells (Johnson et al., 2008) are shown as green dots. *Rest* target genes were significantly upregulated in the *Rest*-deleted non-neuronal tissue (limb). By contrast, the derepression of *Rest* target genes in the brain was not observed following genetic ablation of *Rest*. \*,  $P < 0.01$ ; \*\*,  $P < 0.005$ ; \*\*\*,  $P < 0.05$ .





**Fig. 5. The effect of *Rest* ablation on neurogenesis in vivo.** (A) Southern blot analysis revealed that *Rest* conditional KO (2lox, 9kb) alleles in the adult brain with the *Sox1-Cre* allele recombined to form KO (1lox, 5.3kb) alleles. The wild-type (WT) allele appeared at 7.6 kb. (B) Comparison of brain weight and the ratio of brain weight to body weight in 8-week-old *Rest* conditional KO and control mice. Neither the brain weight nor the ratio was significantly different in *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* adult mice compared with control littermates. (C) The histology of adult brains from *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* mice (8 weeks of age). No histological differences were detectable in the dentate gyrus (DG, middle) of the hippocampus (left) and subventricular zone (SVZ, right) of the brains from *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* versus control adult mice by HE staining. Scale bars: 50  $\mu$ m in DG and SVZ; 500  $\mu$ m in hippocampus.

However, the expression levels of *Syt4* and *Calb1* in the E13.5 brain were significantly lower than those in the adult brain (Fig. 4A). These observations are consistent with the hypothesis that the expression of *Rest* target genes is still repressed in the E13.5 brain in vivo. Since our in vitro experiments revealed that the genetic ablation of *Rest* results in the increased expression of *Rest* target genes in both non-neuronal and neuronal cells, we next tried to dissect the effects of *Rest* ablation on the non-neuronal and neuronal cells in vivo using embryos with floxed *Rest* genes and doxycycline-inducible *Cre* alleles. The *Rest* conditional KO embryos were treated with doxycycline in utero (E8.5-13.5) to induce *Cre*-mediated recombination in both non-neuronal and neuronal cells, and the mice were sacrificed at E13.5 (Fig. 4B). In accordance with the recombination, E13.5 embryos with a *tetO-Cre* allele had decreased signals for GFP when compared with embryos without a *tetO-Cre* allele (Fig. 4B). We also collected the brains and limbs from *Rest*-deleted embryos and their control littermates without the *tetO-Cre* allele. Consistent with the decreased GFP signals, real-time RT-PCR analysis revealed that the expression of *Rest* was significantly downregulated in both the brain and limbs from embryos with a *tetO-Cre* allele compared with those from control littermates (Fig. 4C,D).

Similar to the results obtained in vitro, we detected a significant increase in the expression of *Syt4*, *Tubb3*, *Calb1* and *Stmn2* in the limbs of embryos with the *tetO-Cre* allele (Fig. 4D). By contrast, the expression level of *Tubb3*, *Calb1* and *Stmn2* in the brains of E13.5 embryos with a *tetO-Cre* allele remained repressed, whereas the expression levels of *Rest* and *GFP* itself were downregulated in the same samples (Fig. 4C). Although the expression of *Syt4* was slightly upregulated in the brain of embryos with a *tetO-Cre* allele (Fig. 4C), the effect was only modest when compared with the levels in the adult brain (Fig. 4A). Immunohistochemical analysis confirmed that there was no alteration in the expression pattern of *Tuj1* in the E13.5 brain of embryos with a *tetO-Cre* allele (supplementary material Fig. S8A). We also examined the


expression of *Rest* target genes in the brain or tail of E16.5 embryos with a *tetO-Cre* allele, and found no altered expression levels of these genes in brains, whereas a significant increase in the expression of *Syt4*, *Calb1* and *Stmn2* was observed in the tail (supplementary material Fig. S8B). These results indicate that the *Rest* target genes are specifically derepressed in non-neuronal cells outside of the brain by the genetic ablation of *Rest* in vivo.

We next performed a microarray analysis to determine the changes in gene expression after genetic deletion of *Rest* in E13.5 brain and limb in vivo. Consistent with the results of the real-time RT-PCR analysis, *Rest* target genes were significantly upregulated in the *Rest*-deleted limb tissue (Fig. 4E; genes interacting with *Rest* in ESCs and NPCs are represented by green dots) (Johnson et al., 2008). However, the derepression in the limb tissues (upregulated more than 2-fold after *Rest* ablation) was observed in only a subset of the genes with a *Rest* binding site (27% of the genes; Fig. 4E, limb), suggesting gene-specific derepression. By contrast, only 2% of the genes with a *Rest* binding site were upregulated more than 2-fold in the brain, suggesting that the derepression only occurs at a minority of *Rest* target genes after the genetic ablation of *Rest* (Fig. 4E, brain).

#### In vivo ablation of *Rest* in progenitor cells of the developing brain

*Sox1* was shown to be one of the earliest transcription factors expressed in ectoderm cells committed to a neural fate (Pevny et al., 1998; Takashima et al., 2007). The expression of *Sox1* starts at E7.5-8.5 in the neural tube (Takashima et al., 2007). We used a *Sox1-Cre* allele (Takashima et al., 2007) (*Rest<sup>2lox/2lox</sup>; Sox1-Cre/+*) to excise the floxed *Rest* genes in early progenitor cells of the developing mouse brain in vivo. The brains from *Rest* conditional KO mice carrying the *Sox1-Cre* allele (*Rest<sup>2lox/2lox</sup>; Sox1-Cre/+*) and control littermates (*Rest<sup>2lox/2lox</sup>*) were collected at E13.5, E16.5 and postnatal day (P) 0 and the expression levels of *Rest* target genes were compared by real-time RT-PCR. The brains from





**Fig. 6. Sequential immunohistochemical analysis for Prox1, Dcx, RC2, Tuj1, NeuN, nestin and Gfap.** Brains at E16.5, P4, 8 weeks (8w) and 6 months (6m) of *Rest*-deficient and control mice were analyzed. DG, dentate gyrus; SVZ, subventricular zone. Scale bar: 50  $\mu$ m.

embryos carrying *Sox1-Cre* had significantly lower levels of both *Rest* and *GFP* expression at all time points, reflecting the genetic ablation of *Rest* (supplementary material Fig. S9). However, consistent with the results in the experiments using doxycycline-inducible *Cre* mice, the expression levels of *Rest* target genes such as *Syt4*, *Tubb3*, *Calb1*, *Bdnf* and *Stmn2* (except for *Stmn2* at E13.5) were not significantly increased in the brains of developing embryos with the *Sox1-Cre* allele (supplementary material Fig. S9). These results confirm that the conditional deletion of *Rest* does not substantially affect the expression of *Rest* neuronal target genes in the developing brain.

#### **Rest ablation during adult neurogenesis in vivo**


To further examine the function of *Rest* in the maintenance of neurogenesis in adult brain tissue, we analyzed the brains of adult *Rest* conditional KO mice carrying the *Sox1-Cre* allele. Contrary to our expectation, the *Rest* conditional KO mice carrying the *Sox1-Cre* allele were apparently normal and grew into adults. These mice were viable for more than 1.5 years and were fertile. A Southern blot analysis confirmed that the brains of mice with the *Sox1-Cre* allele had lost the floxed *Rest* genes (Fig. 5A). Despite the lack of *Rest* throughout the entire brain tissue (Fig. 5A), brain weight at 8 weeks of age was not significantly different between the mice with and without the *Sox1-Cre* allele (Fig. 5B).

Next, we examined the histology of the brains of mice with and without the *Sox1-Cre* allele at different developmental stages and ages (E16.5, P0, P4, P7, P10, 4 weeks, 8 weeks, 10 weeks, 6 months and 9 months of age). However, we did not find any histological differences in the brains, including in the subgranular zone (SGZ) of the hippocampal dentate gyrus and the subventricular zone (SVZ), where NSCs and NPCs reside and generate new neurons and glia (Fig. 5C) (Gage, 2002). We further performed immunohistochemical staining to examine the

expression of various markers, including Prox1, Dcx, RC2, Tuj1, NeuN (Rbfox3 – Mouse Genome Informatics), nestin and Gfap at various time points (E16.5, P4, 8 weeks and 6 months) in the *Rest*-deficient and control brains. Prox1, Dcx and RC2 were used as markers for intermediate progenitor cells, immature neuronal cells and radial glial cells, respectively (Gao et al., 2011; Misson et al., 1988). Importantly, we did not observe any difference in the staining patterns of these markers between *Rest*-deficient and control brains (Fig. 6). We also confirmed that nestin-positive cells and Gfap-positive cells did not express Tuj1 in *Rest*-deficient brain, suggesting that misexpression of Tuj1 does not occur in the *Rest*-deficient cells in vivo (supplementary material Figs S10, S11). Although a recent study showed that acute *Rest* ablation in mice leads to a decreased number of Prox1-positive cells at SGZ regions, we did not observe any significant differences in the number of Prox1-positive cells, even in 9-month-old mice (supplementary material Fig. S12).

In order to examine the effect of *Rest* ablation on the maintenance of adult NSCs, we compared the numbers of BrdU-labeled cells in the SVZ of the adult brain of the *Rest* conditional KO mice carrying the *Sox1-Cre* allele with those of control littermates (Doetsch et al., 2002; Lendahl et al., 1990). BrdU was administered as a daily intraperitoneal injection of 50 mg/kg body weight for 12 days starting at the age of 8 weeks, and the brains were fixed 1 day after the last injection as described previously (Shi et al., 2004). We did not find any significant difference in the number of BrdU-positive cells in the SVZ of these mice (Fig. 7A). We also confirmed co-localization of BrdU-positive cells and those positive for Dcx, a marker for premature neuronal cells, in the SVZ of *Rest*-deficient mice (Fig. 7B), suggesting that adult neurogenesis occurs in these mice. In addition, the localization and the number of differentiated NeuN-positive cells in the adult mouse brain did not differ in the presence or absence of the intact *Rest* gene (Fig.





**Fig. 7. Adult neurogenesis in *Rest*-deficient brains in vivo.** (A) Immunohistochemical analysis of BrdU-positive proliferating cells in the adult brain (10 weeks of age). There were no differences in the distribution of BrdU-positive cells in DG and SVZ regardless of genotype. The number of BrdU-positive cells/length of cerebral ventricle in the brains of *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* mice was not altered compared with that of their control littermates. (B) Immunohistochemical staining for BrdU (green) and *Dcx* (red) double-positive cells in the SVZ of brain from *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* mice and control littermates at 10 weeks of age. (C) Immunohistochemical staining for NeuN in the DG of the hippocampus and SVZ of brains from *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* mice and their control littermates at 8 weeks of age. (D) The expression of *Rest* target genes in the adult mouse brain at 8 weeks of age. The expression of *Syt4* and *Calb1* was unchanged in the cerebrum and cerebellum of *Sox1-Cre/+; Rest<sup>2lox/2lox</sup>* mice. Transcript levels were normalized to  $\beta$ -actin levels. The data are presented as average values with s.d. of six independent samples. Scale bars: 50  $\mu$ m in DG and SVZ; 500  $\mu$ m in hippocampus; 20  $\mu$ m in B.

7C). A real-time RT-PCR analysis revealed that the expression of *Syt4* and *Calb1* was not altered in the adult brains lacking the CoRest binding site of *Rest* (Fig. 7D).

These results indicate that *Rest* is not required for brain development and suggest that genetic ablation of *Rest* during the initial stage of neural development does not cause any detectable abnormality in adult neurogenesis in vivo.

## DISCUSSION

Differentiation of neuronal progenitors to mature neurons proceeds with loss of the Rest repressor complex from the RE1 site of neuronal genes, which is accompanied by increased expression of the target genes (Ballas et al., 2005). In the present study, using *Rest* conditional KO mice we confirmed that *Rest* plays a role in the repression of *Rest* neuronal target genes in in vitro cultured neuronal progenitor cells to inhibit terminal differentiation. By contrast, genetic ablation of *Rest* in the whole brain in vivo does not result in altered expression of target genes. Furthermore, mice lacking *Rest* in the brain are apparently normal and grow into adults. These findings suggest that, in contrast to the repressive role of *Rest* in in vitro cultured neuronal cells, *Rest* is dispensable for embryonic neurogenesis in vivo.

The unsolved question is why derepression of *Rest* target genes after *Rest* ablation can be detected in in vitro cultured neuronal cells but not in developing brain tissue in vivo. It has been demonstrated that neuronal progenitor cells are competent for extrinsic signals involved in the specification of cell fate during neurogenesis (Eklund and Jessell, 1999). Our findings suggest that the local environment in the brain, which consists of multiple cell types, is likely to provide complementary regulatory mechanisms for the proper intrinsic regulation of neuronal genes in vivo. It is noteworthy that, in the non-neuronal cells outside of the brain, the derepression of *Rest* target genes was observed not only in vitro but also in vivo. These findings suggest that the brain-specific environment is important for the complementary repression of *Rest* target genes in the absence of *Rest*.

Epigenetic mechanisms serve as important interfaces between gene expression and the environment (Jaenisch and Bird, 2003). Given that *Rest* exerts its repressive effects in conjunction with epigenetic modifiers (Ballas et al., 2005; Naruse et al., 1999; You et al., 2001), it is possible that extrinsic niche signals in the brain compensate for the lack of *Rest* through epigenetic regulatory mechanisms. Consistent with this hypothesis, we could not detect



any differences in the staining pattern of histone H3K27me<sub>3</sub>, a mark of epigenetic silencing, between *Rest* wild-type and *Rest*-deficient brains in vivo (data not shown).

Another study indicated that MeCP2 and other co-repressors remain on the *Rest* target promoters even after loss of *Rest* from the RE1 site, suggesting that *Rest* co-repressors might be involved in the additional regulatory mechanisms that are responsible for repressing the expression of neuronal genes in neuronal cells in the absence of *Rest* (Ballas et al., 2005). It is possible that such factors specifically compensate for the effect of *Rest* ablation in the repression of *Rest* neuronal target genes during embryonic neurogenesis in vivo. It is also possible that transcriptional activators might be required for the derepression of *Rest* target genes in the developing brain. In this context, the decreased levels of transcriptional activation might maintain the proper expression levels of *Rest* target genes in *Rest*-deficient brains in vivo.

A recent study by Gao et al. demonstrated that the acute deletion of *Rest* in the adult dentate gyrus (DG) leads to a decreased number of Prox1-positive DG cells (Gao et al., 2011). However, in the present study, we did not observe any significant differences in the number of Prox1-positive DG cells upon *Rest* ablation, even in 9-month-old mice. A possible explanation for the discrepancy is that the acute deletion of *Rest* in the adult DG cannot activate the compensatory mechanisms, resulting in premature differentiation of adult NSCs, whereas its deletion at the early embryonic stage, as performed in this experiment, activates the complementary machinery that masks *Rest* function at adult stages. Therefore, further experiments are still required to determine the role of *Rest* in the maintenance of adult NSCs in vivo.

The expression of *Rest* target genes in MEFs/TTFs is upregulated upon the loss of *Rest*, suggesting that *Rest* is involved in the active repression of neuronal genes in non-neuronal cells outside of the brain. However, we found that *Bdnf*, which contains RE1 sites and is repressed by *Rest* in ESCs (Yamada et al., 2010), was not derepressed after the deletion of *Rest* in MEFs/TTFs. As reported in a previous study (Chen et al., 1998), these findings suggest that there is cell type specificity of *Rest*-mediated gene silencing. In addition, a microarray analysis revealed that only a subset of genes with a *Rest* binding site (27%) is derepressed by more than 2-fold following genetic ablation of *Rest* in non-neuronal tissues. In addition to the cell type-specific repression, these findings suggest that there is gene-specific repression by *Rest* (Chen et al., 1998). Since epigenetic silencing occurs through multiple modifications, including DNA methylation and histone modifications (Jaenisch and Bird, 2003; Lunyak et al., 2002; Martinowich et al., 2003), *Rest* deletion alone might not be sufficient to reactivate the silenced locus once silencing, involving multiple epigenetic modifications, has been completed. It is also possible that the cell type- and gene-specific activity of transcriptional activators is responsible for such different responses to *Rest* deletion.

The impaired interaction of *Rest* with its target genes has been reported in various neurological and neurodegenerative diseases. Although we found that mice lacking the CoREST binding site of *Rest* in the brain had no gross anatomical abnormalities even upon reaching adulthood, it is possible that more detailed analyses might highlight behavioral abnormalities in the *Rest* KO mice. In this context, these mice might be useful in investigation of the role of altered *Rest* interactions in neurological and neurodegenerative diseases. It would also be interesting to examine the functional alterations of *Rest*-deficient neuronal cells in vivo, which eventually might uncover the pathogenesis of such diseases.

In summary, we have generated *Rest* conditional KO mice and examined the effects of *Rest* ablation in neuronal and non-neuronal cells in vitro and in vivo. We showed that, in contrast to the role of *Rest* in the repression of *Rest* target genes in in vitro cultured neuronal cells, as well as in non-neuronal cells outside of the brain, the CoREST binding site of *Rest* is dispensable for embryonic neurogenesis in vivo.

#### Acknowledgements

We thank Kyoko Takahashi and Ayako Suga for technical assistance; Caroline Beard for the *Col1a-tetOP-cre* allele; and Shinichi Nishikawa for *Sox1-Cre* mice.

#### Funding

This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Precursory Research for Embryonic Science and Technology (PRESTO); and the Ministry of Health, Labour and Welfare of Japan.

#### Competing interests statement

The authors declare no competing financial interests.

#### Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.072272/-DC1>

#### References

- Abrajano, J. J., Qureshi, I. A., Gokhan, S., Zheng, D., Bergman, A. and Mehler, M. F. (2009). Differential deployment of REST and CoREST promotes glial subtype specification and oligodendrocyte lineage maturation. *PLoS ONE* **4**, e7665.
- Andres, M. E., Burger, C., Peral-Rubio, M. J., Battaglioli, E., Anderson, M. E., Grimes, J., Dallman, J., Ballas, N. and Mandel, G. (1999). CoREST: a functional corepressor required for regulation of neural-specific gene expression. *Proc. Natl. Acad. Sci. USA* **96**, 9873-9878.
- Ballas, N., Battaglioli, E., Atouf, F., Andres, M. E., Chenoweth, J., Anderson, M. E., Burger, C., Moniwa, M., Davie, J. R., Bowers, W. J. et al. (2001). Regulation of neuronal traits by a novel transcriptional complex. *Neuron* **31**, 353-365.
- Ballas, N., Grunseich, C., Lu, D. D., Speh, J. C. and Mandel, G. (2005). REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. *Cell* **121**, 645-657.
- Bassuk, A. G., Wallace, R. H., Buhr, A., Buller, A. R., Afawi, Z., Shimojo, M., Miyata, S., Chen, S., Gonzalez-Alegre, P., Griesbach, H. L. et al. (2008). A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. *Am. J. Hum. Genet.* **83**, 572-581.
- Beard, C., Hochedlinger, K., Plath, K., Wutz, A. and Jaenisch, R. (2006). Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. *Genesis* **44**, 23-28.
- Bruce, A. W., Donaldson, I. J., Wood, I. C., Yerbury, S. A., Sadowski, M. I., Chapman, M., Gottgens, B. and Buckley, N. J. (2004). Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. *Proc. Natl. Acad. Sci. USA* **101**, 10458-10463.
- Canzonetta, C., Mulligan, C., Deutsch, S., Ruf, S., O'Doherty, A., Lyle, R., Borel, C., Lin-Marq, N., Delom, F., Groet, J. et al. (2008). DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. *Am. J. Hum. Genet.* **83**, 388-400.
- Chen, Z. F., Paquette, A. J. and Anderson, D. J. (1998). NRSF/REST is required in vivo for repression of multiple neuronal target genes during embryogenesis. *Nat. Genet.* **20**, 136-142.
- Chong, J. A., Tapia-Ramirez, J., Kim, S., Toledo-Aral, J. J., Zheng, Y., Boutros, M. C., Altshuler, Y. M., Frohman, M. A., Kraner, S. D. and Mandel, G. (1995). REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. *Cell* **80**, 949-957.
- Doetsch, F., Petreanu, L., Caille, I., Garcia-Verdugo, J. M. and Alvarez-Buylla, A. (2002). EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. *Neuron* **36**, 1021-1034.
- Edlund, T. and Jessell, T. M. (1999). Progression from extrinsic to intrinsic signaling in cell fate specification: a view from the nervous system. *Cell* **96**, 211-224.
- Fink, T. L., Francis, S. H., Beasley, A., Grimes, K. A. and Corbin, J. D. (1999). Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). *J. Biol. Chem.* **274**, 34613-34620.
- Gage, F. H. (2002). Neurogenesis in the adult brain. *J. Neurosci.* **22**, 612-613.
- Gao, Z., Ure, K., Ding, P., Nashaat, M., Yuan, L., Ma, J., Hammer, R. E. and Hsieh, J. (2011). The master negative regulator REST/NRSF controls adult



- neurogenesis by restraining the neurogenic program in quiescent stem cells. *J. Neurosci.* **31**, 9772-9786.
- Hatano, Y., Yamada, Y., Hata, K., Phutthaphadoong, S., Aoki, H. and Hara, A. (2011). Genetic ablation of a candidate tumor suppressor gene, Rest, does not promote mouse colon carcinogenesis. *Cancer Sci.* **102**, 1659-1664.
- Hochedlinger, K., Yamada, Y., Beard, C. and Jaenisch, R. (2005). Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* **121**, 465-477.
- Jaenisch, R. and Bird, A. (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat. Genet.* **33** Suppl., 245-254.
- Jepsen, K., Hermanson, O., Onami, T. M., Gleiberman, A. S., Lunyak, V., McEvelly, R. J., Kurokawa, R., Kumar, V., Liu, F., Seto, E. et al. (2000). Combinatorial roles of the nuclear receptor corepressor in transcription and development. *Cell* **102**, 753-763.
- Johnson, R., Gambin, R. J., Ooi, L., Bruce, A. W., Donaldson, I. J., Westhead, D. R., Wood, I. C., Jackson, R. M. and Buckley, N. J. (2006). Identification of the REST regulon reveals extensive transposable element-mediated binding site duplication. *Nucleic Acids Res.* **34**, 3862-3877.
- Johnson, R., Teh, C. H., Kunarso, G., Wong, K. Y., Srinivasan, G., Cooper, M. L., Volta, M., Chan, S. S., Lipovich, L., Pollard, S. M. et al. (2008). REST regulates distinct transcriptional networks in embryonic and neural stem cells. *PLoS Biol.* **6**, e256.
- Kohyama, J., Sanosaka, T., Tokunaga, A., Takatsuka, E., Tsujimura, K., Okano, H. and Nakashima, K. (2010). BMP-induced REST regulates the establishment and maintenance of astrocytic identity. *J. Cell Biol.* **189**, 159-170.
- Lendahl, U., Zimmerman, L. B. and McKay, R. D. (1990). CNS stem cells express a new class of intermediate filament protein. *Cell* **60**, 585-595.
- Lepagnol-Bestel, A. M., Zvara, A., Maussion, G., Quignon, F., Ngimbous, B., Ramoz, N., Imbeaud, S., Loe-Mie, Y., Benihoud, K., Agier, N. et al. (2009). DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. *Hum. Mol. Genet.* **18**, 1405-1414.
- Lunyak, V. V., Burgess, R., Prefontaine, G. G., Nelson, C., Sze, S. H., Chenoweth, J., Schwartz, P., Pevzner, P. A., Glass, C., Mandel, G. et al. (2002). Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. *Science* **298**, 1747-1752.
- Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., Fan, G. and Sun, Y. E. (2003). DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. *Science* **302**, 890-893.
- Misson, J. P., Edwards, M. A., Yamamoto, M. and Caviness, V. S., Jr (1988). Identification of radial glial cells within the developing murine central nervous system: studies based upon a new immunohistochemical marker. *Brain Res. Dev. Brain Res.* **44**, 95-108.
- Naruse, Y., Aoki, T., Kojima, T. and Mori, N. (1999). Neural restrictive silencer factor recruits mSin3 and histone deacetylase complex to repress neuron-specific target genes. *Proc. Natl. Acad. Sci. USA* **96**, 13691-13696.
- Otto, S. J., McCorkle, S. R., Hover, J., Conaco, C., Han, J. J., Impey, S., Yochum, G. S., Dunn, J. J., Goodman, R. H. and Mandel, G. (2007). A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. *J. Neurosci.* **27**, 6729-6739.
- Pevny, L. H., Sockanathan, S., Placzek, M. and Lovell-Badge, R. (1998). A role for SOX1 in neural determination. *Development* **125**, 1967-1978.
- Roopra, A., Qazi, R., Schoenike, B., Daley, T. J. and Morrison, J. F. (2004). Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. *Mol. Cell* **14**, 727-738.
- Schoenherr, C. J. and Anderson, D. J. (1995). The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. *Science* **267**, 1360-1363.
- Schoenherr, C. J., Paquette, A. J. and Anderson, D. J. (1996). Identification of potential target genes for the neuron-restrictive silencer factor. *Proc. Natl. Acad. Sci. USA* **93**, 9881-9886.
- Shi, Y., Sawada, J., Sui, G., Affar, E. B., Whetstone, J. R., Lan, F., Ogawa, H., Luke, M. P. and Nakatani, Y. (2003). Coordinated histone modifications mediated by a CtBP co-repressor complex. *Nature* **422**, 735-738.
- Shi, Y., Chichung Lie, D., Taupin, P., Nakashima, K., Ray, J., Yu, R. T., Gage, F. H. and Evans, R. M. (2004). Expression and function of orphan nuclear receptor TLX in adult neural stem cells. *Nature* **427**, 78-83.
- Strutz, F., Okada, H., Lo, C. W., Danoff, T., Carone, R. L., Tomaszewski, J. E. and Neilson, E. G. (1995). Identification and characterization of a fibroblast marker: FSP1. *J. Cell Biol.* **130**, 393-405.
- Takashima, Y., Era, T., Nakao, K., Kondo, S., Kasuga, M., Smith, A. G. and Nishikawa, S. (2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. *Cell* **129**, 1377-1388.
- Tapia-Ramirez, J., Eggen, B. J., Peral-Rubio, M. J., Toledo-Aral, J. J. and Mandel, G. (1997). A single zinc finger motif in the silencing factor REST represses the neural-specific type II sodium channel promoter. *Proc. Natl. Acad. Sci. USA* **94**, 1177-1182.
- Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Sudhof, T. C. and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* **463**, 1035-1041.
- Yamada, Y., Aoki, H., Kunisada, T. and Hara, A. (2010). Rest promotes the early differentiation of mouse ESCs but is not required for their maintenance. *Cell Stem Cell* **6**, 10-15.
- You, A., Tong, J. K., Grozinger, C. M. and Schreiber, S. L. (2001). CoREST is an integral component of the CoREST-human histone deacetylase complex. *Proc. Natl. Acad. Sci. USA* **98**, 1454-1458.
- Zuccato, C., Belyaev, N., Conforti, P., Ooi, L., Tartari, M., Papadimitou, E., MacDonald, M., Fossale, E., Zeitlin, S., Buckley, N. et al. (2007). Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. *J. Neurosci.* **27**, 6972-6983.



# Genetic ablation of a candidate tumor suppressor gene, *Rest*, does not promote mouse colon carcinogenesis

Yuichiro Hatano,<sup>1</sup> Yasuhiro Yamada,<sup>2,3,5</sup> Kazuya Hata,<sup>1</sup> Suphot Phutthaphadoong,<sup>1</sup> Hitomi Aoki<sup>4</sup> and Akira Hara<sup>1</sup>

<sup>1</sup>Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu; <sup>2</sup>PRESTO, Japan Science and Technology Agency, Saitama;

<sup>3</sup>Center for iPS Cell Research and Application, Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto; <sup>4</sup>Department of Tissue and Organ Development, Gifu University Graduate School of Medicine, Gifu, Japan

(Received March 23, 2011/Revised May 30, 2011/Accepted June 7, 2011/Accepted manuscript online June 11, 2011/Article first published online July 21, 2011)

Colon carcinogenesis is a multistage process involving genetic alterations of various tumor suppressor genes and oncogenes. Repressor element 1 silencing factor (*REST*), which was originally discovered as a transcriptional repressor of neuronal genes, plays an important role in neuronal differentiation. In a previous genetic screening for tumor suppressor genes in human cancers, *REST* was identified as a candidate tumor suppressor gene in colorectal carcinogenesis. However, the role of *Rest* in colon carcinogenesis *in vivo* remains unclear because of the embryonic lethal phenotype of the conventional *Rest* knockout mouse. In the present study, we conditionally deleted the *Rest* gene in the intestinal epithelium and investigated the effect of *Rest* ablation in mouse colon tumorigenesis. A conditional ablation of *Rest* in the colonic crypts led to a rapid upregulation of *Rest*-targeted genes, such as *Syt4*, *Bdnf*, and *Tubb3*, suggesting that *Rest* actually suppresses the expression of its target genes in the colon. However, *Rest* ablation did not lead to any significant effect on the development of colon tumors in two independent mouse models of colon carcinogenesis. In addition, despite the upregulation of neuronal genes in the colonic crypts, no neuronal differentiation was observed in the colonic crypts and tumors after the *Rest* ablation. These results indicate that the loss of *Rest* expression by itself does not promote the development of colon tumors in mice, and suggest that *REST* may exert a tumor suppressing activity in conjunction with the additional genetic/epigenetic abnormalities that occur during colon carcinogenesis. (*Cancer Sci* 2011; 102: 1659–1664)

**R**epressor element 1 silencing factor (*REST*; also called neuron-restrictive silencing factor [NRSF]) was originally discovered as a transcriptional repressor of a number of neuronal genes.<sup>(1,2)</sup> *REST* binds to a conserved 21–23 bp motif known as repressor element 1 within the control regions of target genes, and recruits multiple co-factors through repressor domains to alter epigenetic modifications, leading to the generation of a silencing complex. *REST* is ubiquitously expressed in non-neuronal cells,<sup>(3)</sup> and it prevents neuronal gene expression in non-neuronal cells.<sup>(4)</sup>

A link between *REST* dysfunction and carcinogenesis has been recognized<sup>(5–7)</sup> in a number of cancers such as prostate cancer,<sup>(8)</sup> breast cancer,<sup>(9–11)</sup> small cell lung cancer,<sup>(12–16)</sup> medulloblastoma,<sup>(17–19)</sup> and neuroblastoma.<sup>(20–23)</sup> In an RNAi-based screening for tumor suppressor genes, *REST* was identified as a candidate novel tumor suppressor gene.<sup>(24)</sup> Consistent with this notion, a *REST* mutation was identified in a colon cancer cell line, DLD-1, and the *REST* locus is deleted in approximately one-third of human colon cancers (14 of 42 primary tumors and 13 of 38 cell lines).<sup>(24)</sup> In addition, exogenous *REST* has been shown to suppress the growth of the colon cancer cells that lack *REST* expression, suggesting that *REST* actually plays

a role in the tumor suppression *in vitro*. Although *REST*-mediated cellular transformation is proposed to be associated with the PI3K pathway, the precise mechanism(s) underlying the involvement of *REST* in colon carcinogenesis remain unclear. In particular, there is no *in vivo* evidence that establishes the function of *Rest* in tumor suppression.

In the present study, we examined the effect of genetic ablation of *Rest* during colon carcinogenesis *in vivo*. We herein show that genetic deletion of *Rest* results in derepression of the *Rest*-targeted neuronal genes in the colonic crypts, however, *Rest* ablation does not promote mouse colon carcinogenesis.

## Materials and Methods

**Animals.** All animal experiments were approved by the Animal Research Committee of the Graduate School of Medicine, Gifu University (Gifu, Japan). In a previous study, homozygous *Rest* knockout (KO) mice showed embryonic lethality around E10.5, with a growth retardation phenotype.<sup>(25)</sup> In the present study, in order to investigate the effect of *Rest* deletion on colon carcinogenesis *in vivo*, we used mice expressing conditional knockout alleles of *Rest*.<sup>(26)</sup> In the *Rest* conditional mice, the endogenous *Rest* loci were replaced by the conditional KO alleles carrying the floxed last exon, which encodes the CoRest binding site that is essential for the generation of the silencing complex.<sup>(27)</sup> An *ires-Gfp* sequence was inserted into the 3'-UTR of the *Rest* gene to monitor the transcription of the modified allele (*Rest*<sup>2lox</sup> allele). The *Rest*<sup>2lox</sup> allele was recombined into the *Rest*<sup>1lox</sup> allele in the presence of Cre recombinase. Despite the presence of the remaining exons 1–3 of the *Rest*<sup>1lox</sup> allele, altered *Rest* transcripts were not detected in *Rest*<sup>1lox/1lox</sup> mouse embryonic stem cells,<sup>(26)</sup> thus suggesting the 1lox allele to be equivalent to the conventional KO allele.

*Apc*<sup>Min/+</sup> mice, doxycycline-inducible *Cre* mice, and intestinal epithelium-specific *Cre*-expressing (*Fabp-Cre*) mice were described previously.<sup>(26,28,29)</sup> Doxycycline-inducible *Cre* mice harbor two transgenes, *Rosa26-M2rtTA* and *CollA1-tetO-Cre*.<sup>(26)</sup> The experimental mice were obtained by breeding.

**Experimental procedures.** We tested the effect of *Rest* ablation in mouse colon carcinogenesis in two independent experiments (Fig. 1). The first experiment (protocol 1) was a chemically-induced colon carcinogenesis model using doxycycline-inducible *Cre*-expressing mice. The other experiment (protocol 2) used the *Apc*<sup>Min/+</sup> mouse colon carcinogenesis model combined with the *Fabp-Cre* mouse. In protocol 1, Cre recombinase was induced by doxycycline treatment after carcinogen exposure, mimicking when the *Rest* gene is lost after the initiation phase of carcinogenesis. In contrast, in protocol 2,

<sup>5</sup>To whom correspondence should be addressed.  
E-mail: y-yamada@cira.kyoto-u.ac.jp